News | January 08, 2013

Angioslide Completes $6.3 Million Financing to Extend Embolic Capture System

Angioslide TriVentures Financing Embolic Protection Devices PAD

January 8, 2013 — Angioslide announced the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments to complete the round.

“Proceeds from this Series C round will be used to continue U.S. market expansion, improve our product offering and validate the technology in additional vascular beds,” said Lihu Avitov, Angioslide CEO. “The financing will help us fuel our growth. We are excited to have TriVentures join our efforts and appreciate the ongoing support from Viola Partners, Agate and XT Investments.”

Angioslide is transforming peripheral angioplasty by combining PTA balloon intervention with debris capture and removal. The Proteus device removes some of the embolic particles released during peripheral interventions, enabling physicians to improve procedural outcomes in challenging interventions. Angioslide's above-the-knee product line was recently expanded to include a below-the-knee, low-profile 0.014-inch platform. 

Over 10 million people suffer from peripheral artery disease (PAD) in the United States alone. In recent years, catheter-based interventions have become the primary therapeutic approach for these patients. With the increase in life expectancy, diabetes prevalence and number of high-risk patients, physicians are seeking to expand the current interventional “tool box” to improve procedure outcomes.

"Angioslide is a very exciting opportunity that can truly help PAD patients reconstitute their vascular flow," said Michal Geva, co-founder and a managing partner of TriVentures. "This is one of TriVentures' first investments in which the clinical, regulatory and commercial challenges are mitigated, and we look forward to working with the team in bringing this technology to expanded commercialization in the U.S."

Related Content

Boston Scientific Closes Claret Medical Acquisition, Announces Positive Reimbursement Decision
News | Embolic Protection Devices | August 03, 2018
Boston Scientific Corp. announced it has recently closed its acquisition of Claret Medical Inc., a privately-held...
Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke.

Claret's FDA-cleared Sentinel Cerebral Embolic Protection System for TAVR will expand Boston Scientific's structural heart portfolio. It collects emboli knocked loose that would otherwise lodge in the brain and potentially cause a stroke. 

News | Embolic Protection Devices | July 20, 2018
July 20, 2018 — Boston Scientific Corp.
The Emboliner Embolic Protection Catheteris designed to capture debris released from the valve and vessel walls during transcatheter aortic valve replacement (TAVR) procedures.

The Emboliner Embolic Protection Catheter is designed to capture debris released from the valve and vessel walls during transcatheter aortic valve replacement (TAVR) procedures. It allows for the passage of other catheters during TAVR procedures. 

News | Embolic Protection Devices | June 07, 2018
June 7, 2018 — The first clinical cases have been completed where the Emboliner...
Sentinel Cerebral Protection System Reduces TAVR Strokes More Than 60 Percent
News | Embolic Protection Devices | May 08, 2018
May 8, 2018 — One-year results from the Sentinel Cerebral Protection System show it can reduce the incidence of...
Emboline Inc. Completes Funding for TAVR Embolic Protection Trial
News | Embolic Protection Devices | April 20, 2018
Emerging medical device company Emboline Inc. announced it has completed a Series B funding round totaling over $10...
Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.
News | Embolic Protection Devices | February 19, 2018
Claret Medical announced that since U.S. Food and Drug Administration (FDA) clearance in June 2017, its Sentinel...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the
Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System
News | Embolic Protection Devices | October 23, 2017
October 23, 2017 — Claret Medical announced that it has closed on a Series C financing of $14.5 million led by Lights
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices | September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices | September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Overlay Init